MDXG
NEUTRAL
$3.92
Live
MiMedx Group, Inc. · NASDAQ
Target $9.67
(+146.6%)
$3.77
52W Range
$7.99
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$582.38M
P/E
12.25
ROE
21.6%
Profit margin
11.6%
Debt/Equity
0.09
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
MDXG presents a stark divergence between fundamental value and market sentiment. With a Piotroski F-Score of 4/9 (Stable) and an exceptionally clean balance sheet (Debt/Equity 0.09), the company is financially healthy and significantly undervalued relative to its Intrinsic Value of $9.44 and Analyst Target of $9.67. However, the assessment is tempered to neutral due to a severe technical collapse (0/100 trend) and bearish insider activity, suggesting that while the stock is a value bargain, it lacks a current catalyst for reversal.
Key Strengths
Exceptional balance sheet with very low Debt/Equity (0.09)
Strong profitability with 82.56% gross margins and 21.61% ROE
Impressive earnings growth (99.50% YoY)
High liquidity indicated by a Current Ratio of 4.32
Significant valuation gap between current price ($3.92) and intrinsic value ($9.44)
Key Risks
Severe bearish technical trend (0/100) and 1-year price decline of 42.1%
Bearish insider sentiment with recent selling activity
Lack of dividend support for long-term holders
Market disregard for strong earnings beats (3/4 quarters)
Potential sector-specific volatility in biotechnology
AI Fair Value Estimate
Based on comprehensive analysis
$6.48
+65.3% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
56
Moderate
90
85
30
75
0
AI Verdict
Fundamental Value Trap
Key drivers: Strong growth and margins, Extreme technical weakness, Deep valuation discount
Confidence
80%
Value
90/100
Ref P/E, PEG, Graham Number
Positives
- P/E of 12.25 is very low for the sector
- Price is near Graham Number ($3.53)
- Trades at a steep discount to Intrinsic Value
Watchpoints
- Price/Book is slightly elevated at 2.26
Future
85/100
Ref Growth rates
Positives
- Revenue growth of 27.10%
- Earnings growth of 99.50%
- Consistent earnings beats
Watchpoints
- Forward P/E is higher than trailing P/E, suggesting slowing growth expectations
Past
30/100
Ref Historical trends
Positives
- Recent transition to consistent profitability
Watchpoints
- 5-year change of -67.5%
- 1-year change of -42.1%
Health
75/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Very low debt levels
- Strong current and quick ratios
Watchpoints
- Piotroski F-Score is only 4/9, indicating stable but not strong health
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.92
Analyst Target
$9.67
Upside/Downside
+146.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MDXG and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MDXG
MiMedx Group, Inc.
Primary
|
-67.5% | +18.4% | -42.1% | -39.8% | -10.5% | +1.0% |
|
LYEL
Lyell Immunopharma, Inc.
Peer
|
-92.7% | -47.5% | +178.7% | +47.4% | +16.7% | +14.3% |
|
HSTM
HealthStream, Inc.
Peer
|
-8.4% | -25.8% | -36.2% | -22.1% | -3.1% | -2.8% |
|
IRWD
Ironwood Pharmaceuticals, Inc.
Peer
|
-64.3% | -66.3% | +259.4% | +128.3% | -1.4% | +2.5% |
|
BVS
Bioventus Inc.
Peer
|
-36.8% | +662.1% | +6.9% | +32.9% | +2.7% | -3.2% |
MDX
MiMedx Group, Inc.
Primary
5Y
-67.5%
3Y
+18.4%
1Y
-42.1%
6M
-39.8%
1M
-10.5%
1W
+1.0%
LYE
Lyell Immunopharma, Inc.
Peer
5Y
-92.7%
3Y
-47.5%
1Y
+178.7%
6M
+47.4%
1M
+16.7%
1W
+14.3%
HST
HealthStream, Inc.
Peer
5Y
-8.4%
3Y
-25.8%
1Y
-36.2%
6M
-22.1%
1M
-3.1%
1W
-2.8%
IRW
Ironwood Pharmaceuticals, Inc.
Peer
5Y
-64.3%
3Y
-66.3%
1Y
+259.4%
6M
+128.3%
1M
-1.4%
1W
+2.5%
BVS
Bioventus Inc.
Peer
5Y
-36.8%
3Y
+662.1%
1Y
+6.9%
6M
+32.9%
1M
+2.7%
1W
-3.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
12.25
Forward P/E
15.22
PEG Ratio
N/A
P/B Ratio
2.26
P/S Ratio
1.39
EV/Revenue
1.05
EV/EBITDA
5.56
Market Cap
$582.38M
Profitability
Profit margins and return metrics
Profit Margin
11.6%
Operating Margin
17.85%
Gross Margin
82.56%
ROE
21.61%
ROA
13.17%
Growth
Revenue and earnings growth rates
Revenue Growth
+27.1%
Earnings Growth
+99.5%
Q/Q Revenue Growth
+27.11%
Q/Q Earnings Growth
+104.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.09
Low debt
Current Ratio
4.32
Strong
Quick Ratio
3.76
Excellent
Cash/Share
$1.12
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
83.9%
Op. Margin
17.8%
Net Margin
12.9%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.34x
Operating CF
$0.0B
Free Cash Flow
$0.0B
FCF Yield
114%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-29
$N/A
2026-02-25
$0.14
+30.2% surprise
2025-10-29
$0.15
+100.0% surprise
2025-07-30
$0.1
+81.8% surprise
Healthcare Sector Comparison
Comparing MDXG against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
P/E Ratio
12.25
This Stock
vs
88.11
Sector Avg
-86.1%
(Discount)
Return on Equity (ROE)
21.61%
This Stock
vs
-86.0%
Sector Avg
-125.1%
(Below Avg)
Profit Margin
11.6%
This Stock
vs
-11.76%
Sector Avg
-198.7%
(Weaker)
Debt to Equity
0.09
This Stock
vs
3.51
Sector Avg
-97.5%
(Less Debt)
Revenue Growth
27.1%
This Stock
vs
90.15%
Sector Avg
-69.9%
(Slower)
Current Ratio
4.32
This Stock
vs
3.67
Sector Avg
+17.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MDXG
MiMedx Group, Inc.
|
NEUTRAL | $582.38M | 12.25 | 21.6% | 11.6% | $3.92 | |
|
LYEL
Lyell Immunopharma, Inc.
|
BEARISH | $578.54M | - | -87.0% | -% | $24.8 | Compare |
|
HSTM
HealthStream, Inc.
|
BEARISH | $589.8M | 32.59 | 5.1% | 6.0% | $19.88 | Compare |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
BEARISH | $591.9M | 24.2 | -% | 8.1% | $3.63 | Compare |
|
BVS
Bioventus Inc.
|
BEARISH | $595.53M | 26.79 | 13.2% | 4.0% | $8.84 | Compare |
MDXG
MiMedx Group, Inc.
NEUTRAL
Mkt Cap
$582M
P/E
12.2
ROE
21.6%
Price
$3.92
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | DOUGLAS RICE C | Chief Financial Officer | Option Exercise | 243,000 | $1,093,500 |
| 2026-03-10 | HULSE WILLIAM FRANK IV | General Counsel | Option Exercise | 136,364 | $613,638 |
| 2026-03-10 | MAERSK-MOLLER KIMBERLY | Officer | Option Exercise | 42,845 | $192,802 |
| 2026-03-04 | CAPPER JOSEPH H | Chief Executive Officer | Stock Award | 371,094 | - |
| 2026-03-04 | DOUGLAS RICE C | Chief Financial Officer | Stock Award | 74,163 | - |
| 2026-03-04 | HULSE WILLIAM FRANK IV | General Counsel | Stock Award | 74,987 | - |
| 2026-03-04 | WHITLOW RICCI S | Chief Operating Officer | Stock Award | 74,163 | - |
| 2026-03-04 | MAERSK-MOLLER KIMBERLY | Officer | Stock Award | 74,163 | - |
| 2025-11-06 | MAERSK-MOLLER KIMBERLY | Officer | Sale | 58,300 | $432,329 |
DOUGLAS RICE C
Chief Financial Officer
2026-03-10
243,000 shares
·
$1,093,500
HULSE WILLIAM FRANK IV
General Counsel
2026-03-10
136,364 shares
·
$613,638
MAERSK-MOLLER KIMBERLY
Officer
2026-03-10
42,845 shares
·
$192,802
CAPPER JOSEPH H
Chief Executive Officer
2026-03-04
371,094 shares
DOUGLAS RICE C
Chief Financial Officer
2026-03-04
74,163 shares
HULSE WILLIAM FRANK IV
General Counsel
2026-03-04
74,987 shares
WHITLOW RICCI S
Chief Operating Officer
2026-03-04
74,163 shares
MAERSK-MOLLER KIMBERLY
Officer
2026-03-04
74,163 shares
MAERSK-MOLLER KIMBERLY
Officer
2025-11-06
58,300 shares
·
$432,329
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
Citizens
2026-02-23
Market Outperform
Cantor Fitzgerald
2026-02-17
Overweight
Overweight
Lake Street
2026-01-20
Buy
Buy
Mizuho
2025-12-17
Outperform
Outperform
Past News Coverage
Recent headlines mentioning MDXG from our newsroom.
Newest → oldest
No matching news yet.